Menu Search
Equities

Amarin Corporation PLC

EH3A:DUS

Amarin Corporation PLC

Actions
  • Price (EUR)0.535
  • Today's Change0.00 / 0.00%
  • Shares traded349.00
  • 1 Year change-20.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 11:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

  • Revenue in USD (TTM)241.02m
  • Net income in USD-39.35m
  • Incorporated1989
  • Employees275.00
  • Location
    Amarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
  • Phone+353 16699020
  • Websitehttps://amarincorp.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.